Vancouver-based Kardium has closed a US$250 million financing round to advance the commercialization of its Globe System for atrial fibrillation treatment. The oversubscribed round included Janus Henderson Investors, Qatar Investment Authority, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital.
The Globe System features a 122-electrode array enabling rapid pulmonary vein isolation and high-resolution mapping in a single catheter. CEO Kevin Chaplin said the funding will expand manufacturing, support regulatory approvals, and build a commercial team ahead of launch later this year. Clinical data showed 78% freedom from arrhythmia at one year in paroxysmal AF patients.
Want to know more? Check out the source code on Techcouver.com.